Abstract:Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. Summary: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques. Key Message: Advances in image-guided locoregional therapies, including local ablative therapy and transarterial therapy, have led to a major breakthrough in the management of HCC. Both survival rates and cure rates of patients with HCC have improved markedly since the introduction of these techniques. Practical Implications: Radiofrequency ablation is currently considered as an alternative to surgical resection for patients with early-stage HCC. A newer technique of ablation such as microwave ablation is increasingly being used, especially for large HCC. Transarterial chemoembolization has become a standard care for asymptomatic patients with multinodular tumors in intermediate-stage disease, and transarterial radioembolization has become the method of choice in HCC cases with portal vein thrombosis. Moreover, combination treatment modalities, such as thermal-based ablation combined with transarterial chemoembolization or 125I seed implant brachytherapy, may further broaden their clinical indications for HCC. Moreover, use of localized radiation in combination with thermal ablation has been reported to improve tumor control and long-term survival.

Cover Image, Volume 43, Issue 9

Back Cover Image, Volume 40, Issue 2

Cover Image, Volume 42, Issue 1

Cover Image, Volume 43, Issue 11

Back Cover Image, Volume 120, Number 7, July 2023

Editorial: Interventional Therapy of Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Cover Image, Volume 95, Number 2, February 2023

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Cytotoxic immune cell-based immunotherapy for hepatocellular carcinoma

Cover Image, Volume 58, Number 1, January 2023

New advances in the treatment of intermediate and advanced hepatocellular carcinoma

Supplementary Figures 1-8 from Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma

Table S3 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Advanced HCC Patient Benefit from Neoantigen Reactive T Cells Based Immunotherapy: A Case Report

Table S4 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

Recent Advances in Hepatocellular Carcinoma Therapeutic Strategies and Imaging-Guided Treatment